What: A study of nearly 600 women with early-stage breast cancer found 47% chose to continue hormone-based treatment beyond the recommended 5 years, aiming for 10 years total. Factors that influenced their decision included their oncologist’s advice, fear of the cancer returning, and a desire for more extensive treatment.

Key Line: “This study emphasizes the importance of a shared decision-making approach among cancer patients, oncologists and primary care physicians that may need to be revisited over time. This type of shared decision-making is becoming more common – and more necessary – as patients have more treatment options and decisions to make,” said co-senior author Sarah Hawley, Ph.D., M.P.H.

Source: University of Michigan